Cargando…
P1094: SAFETY AND EFFICACY OF ACALABRUTINIB, BENDAMUSTINE, AND RITUXIMAB IN PATIENTS WITH TREATMENT-NAIVE OR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: PHASE IB TRIAL
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431176/ http://dx.doi.org/10.1097/01.HS9.0000971272.64204.bc |
| _version_ | 1785091139294986240 |
|---|---|
| author | Phillips, Tycel Wang, Michael Robak, Tadeusz Gallinson, David Stevens, Don Patel, Krish Ramadan, Safaa Wun, Chuan-Chaun Jurczak, Wojciech Smith, Stephen D. |
| author_facet | Phillips, Tycel Wang, Michael Robak, Tadeusz Gallinson, David Stevens, Don Patel, Krish Ramadan, Safaa Wun, Chuan-Chaun Jurczak, Wojciech Smith, Stephen D. |
| author_sort | Phillips, Tycel |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10431176 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104311762023-08-17 P1094: SAFETY AND EFFICACY OF ACALABRUTINIB, BENDAMUSTINE, AND RITUXIMAB IN PATIENTS WITH TREATMENT-NAIVE OR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: PHASE IB TRIAL Phillips, Tycel Wang, Michael Robak, Tadeusz Gallinson, David Stevens, Don Patel, Krish Ramadan, Safaa Wun, Chuan-Chaun Jurczak, Wojciech Smith, Stephen D. Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10431176/ http://dx.doi.org/10.1097/01.HS9.0000971272.64204.bc Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Phillips, Tycel Wang, Michael Robak, Tadeusz Gallinson, David Stevens, Don Patel, Krish Ramadan, Safaa Wun, Chuan-Chaun Jurczak, Wojciech Smith, Stephen D. P1094: SAFETY AND EFFICACY OF ACALABRUTINIB, BENDAMUSTINE, AND RITUXIMAB IN PATIENTS WITH TREATMENT-NAIVE OR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: PHASE IB TRIAL |
| title | P1094: SAFETY AND EFFICACY OF ACALABRUTINIB, BENDAMUSTINE, AND RITUXIMAB IN PATIENTS WITH TREATMENT-NAIVE OR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: PHASE IB TRIAL |
| title_full | P1094: SAFETY AND EFFICACY OF ACALABRUTINIB, BENDAMUSTINE, AND RITUXIMAB IN PATIENTS WITH TREATMENT-NAIVE OR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: PHASE IB TRIAL |
| title_fullStr | P1094: SAFETY AND EFFICACY OF ACALABRUTINIB, BENDAMUSTINE, AND RITUXIMAB IN PATIENTS WITH TREATMENT-NAIVE OR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: PHASE IB TRIAL |
| title_full_unstemmed | P1094: SAFETY AND EFFICACY OF ACALABRUTINIB, BENDAMUSTINE, AND RITUXIMAB IN PATIENTS WITH TREATMENT-NAIVE OR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: PHASE IB TRIAL |
| title_short | P1094: SAFETY AND EFFICACY OF ACALABRUTINIB, BENDAMUSTINE, AND RITUXIMAB IN PATIENTS WITH TREATMENT-NAIVE OR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: PHASE IB TRIAL |
| title_sort | p1094: safety and efficacy of acalabrutinib, bendamustine, and rituximab in patients with treatment-naive or relapsed/refractory mantle cell lymphoma: phase ib trial |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431176/ http://dx.doi.org/10.1097/01.HS9.0000971272.64204.bc |
| work_keys_str_mv | AT phillipstycel p1094safetyandefficacyofacalabrutinibbendamustineandrituximabinpatientswithtreatmentnaiveorrelapsedrefractorymantlecelllymphomaphaseibtrial AT wangmichael p1094safetyandefficacyofacalabrutinibbendamustineandrituximabinpatientswithtreatmentnaiveorrelapsedrefractorymantlecelllymphomaphaseibtrial AT robaktadeusz p1094safetyandefficacyofacalabrutinibbendamustineandrituximabinpatientswithtreatmentnaiveorrelapsedrefractorymantlecelllymphomaphaseibtrial AT gallinsondavid p1094safetyandefficacyofacalabrutinibbendamustineandrituximabinpatientswithtreatmentnaiveorrelapsedrefractorymantlecelllymphomaphaseibtrial AT stevensdon p1094safetyandefficacyofacalabrutinibbendamustineandrituximabinpatientswithtreatmentnaiveorrelapsedrefractorymantlecelllymphomaphaseibtrial AT patelkrish p1094safetyandefficacyofacalabrutinibbendamustineandrituximabinpatientswithtreatmentnaiveorrelapsedrefractorymantlecelllymphomaphaseibtrial AT ramadansafaa p1094safetyandefficacyofacalabrutinibbendamustineandrituximabinpatientswithtreatmentnaiveorrelapsedrefractorymantlecelllymphomaphaseibtrial AT wunchuanchaun p1094safetyandefficacyofacalabrutinibbendamustineandrituximabinpatientswithtreatmentnaiveorrelapsedrefractorymantlecelllymphomaphaseibtrial AT jurczakwojciech p1094safetyandefficacyofacalabrutinibbendamustineandrituximabinpatientswithtreatmentnaiveorrelapsedrefractorymantlecelllymphomaphaseibtrial AT smithstephend p1094safetyandefficacyofacalabrutinibbendamustineandrituximabinpatientswithtreatmentnaiveorrelapsedrefractorymantlecelllymphomaphaseibtrial |